Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, announces that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). “Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty therapeutics company, focused on addressing significant unmet medical needs,” said Evan Loh, MD, Chief Executive Officer of Paratek.
Read the full article: Paratek Pharmaceuticals Completes Acquisition of Optinose //
Source: https://www.globenewswire.com/news-release/2025/05/21/3085707/0/en/Paratek-Pharmaceuticals-Completes-Acquisition-of-Optinose-Creating-an-Expanded-Portfolio-of-Specialty-Therapies.html